Using conservative figures and estimates (generous to...

Using conservative figures and estimates (generous to Starpharma), I would say that as of today, the cash balance would be approximately $28.1m.

In the absence of new licence income and cash deals, and in the absence of a sharp turnaround in revenue from VivaGel BV, condoms and Viraleze, I estimate the cash balance will be approximately $26.5m in next months Quarterly Report.

I can’t help but feel that if there’s no DEP deal imminent, and I see no reason to believe there will be, then we are inching towards capital raising territory in late Q2 or in Q3 of this CY.

Whilst the running down of current in-house DEP Phase 2 programs will help, there may need to be additional belt trimming and cost reductions across the company that could include directors salaries, staff head count etc

We need some seriously positive news and developments involving cold hard cash, and soon. More research agreements and no-fee Viraleze territory licences will not move the dial.